-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, AstraZeneca's Global R&D China Center announced a cooperation with Genetron Health Technology
.
According to the agreement, the two parties will jointly invest and cooperate in solid tumor MRD research and development.
Based on the gene mutation profile of each patient's primary tumor, they will jointly develop and verify personalized customized MRD detection products for efficacy evaluation and tumor recurrence monitoring
.
At the same time, the two parties will establish a joint committee to oversee product development
.
In addition, AstraZeneca also plans to apply the above-mentioned products developed in cooperation with Genetron Health to clinical trials involving customized solid tumor MRD detection in China
.
It is understood that Genetron Health focuses on the research and application of cancer genomics, and mainly provides products and services covering the entire cancer cycle, such as early cancer screening, medication guidance, prognostic monitoring, and new tumor drug development services
.
This cooperation is not the first time AstraZeneca has cooperated with Genetron Health in the field of oncology
.
As early as 2019, AstraZeneca and Genetron Health signed an in-depth strategic cooperation agreement to carry out in-depth cooperation on precision medicine
.
The industry predicts that in the future, the scope of cooperation between the two parties is expected to expand to the IVD registration and full commercialization of the product
.
It is worth noting that, in addition to AstraZeneca, cooperation between pharmaceutical companies on precise tumor diagnosis is actually not uncommon
.
On November 23, Jiuqiang Biotech and Zhongkonate held a cooperation signing ceremony
.
This in-depth cooperation between the two parties includes two levels: one is the equity investment of Nine Biotech Co.
, Ltd.
; the other is the signing of a sales cooperation agreement between Nine Biotech and China Conatech, becoming the head of the domestic medical institution for the entire line of CTC products of China Conatech.
Dealer
.
It is expected that through this cooperation, Zhongkenatei's technical advantages in the field of CTC liquid biopsy will be organically combined with the powerful channel capabilities of the nine-strong biological in the field of inspection, and jointly create a professional enterprise for multi-faceted accurate tumor diagnosis
.
On November 7, Roche Diagnostics (Shanghai) Co.
, Ltd.
also announced a strategic partnership with Preh Benchmark at the 4th China International Import Expo.
.
This cooperation will combine the technical advantages of both parties in the field of precision medicine to jointly promote the development and cooperation of precision tumor diagnosis, and promote the realization of clinical precision diagnosis and treatment
.
Analysis believes that a large number of companies are vying to deploy in the field of accurate tumor diagnosis.
In fact, they are mainly optimistic about the development prospects of China's diagnostic industry
.
It is understood that in recent years, the financing environment of China's diagnostic and genetic testing industry has begun to tighten further, with significant head effects in the field of private equity financing, and genetic testing companies are at the forefront in both the number of transactions and the amount of financing
.
In addition, since the launch of the Sci-tech Innovation Board, IVD has also become a popular segment in the biomedical sector; the M&A market has completed two major transactions exceeding RMB 1 billion throughout the year
.
At the same time, more than half of financing transactions in overseas markets are also completed by genetic testing companies
.
In this context, industry insiders believe that in the medium and long term, as people’s consumption levels upgrade, the number of patients with chronic diseases and the increase in health awareness due to the increasing aging of our country will be used in disease risk prediction and health management.
With higher requirements and demands in chronic disease management and other aspects, the diagnostic testing industry will continue to be valued, and the market will further expand
.
Affected by this, China's medical diagnosis-related enterprises are also expected to usher in continued benefits
.
.
According to the agreement, the two parties will jointly invest and cooperate in solid tumor MRD research and development.
Based on the gene mutation profile of each patient's primary tumor, they will jointly develop and verify personalized customized MRD detection products for efficacy evaluation and tumor recurrence monitoring
.
At the same time, the two parties will establish a joint committee to oversee product development
.
In addition, AstraZeneca also plans to apply the above-mentioned products developed in cooperation with Genetron Health to clinical trials involving customized solid tumor MRD detection in China
.
It is understood that Genetron Health focuses on the research and application of cancer genomics, and mainly provides products and services covering the entire cancer cycle, such as early cancer screening, medication guidance, prognostic monitoring, and new tumor drug development services
.
This cooperation is not the first time AstraZeneca has cooperated with Genetron Health in the field of oncology
.
As early as 2019, AstraZeneca and Genetron Health signed an in-depth strategic cooperation agreement to carry out in-depth cooperation on precision medicine
.
The industry predicts that in the future, the scope of cooperation between the two parties is expected to expand to the IVD registration and full commercialization of the product
.
It is worth noting that, in addition to AstraZeneca, cooperation between pharmaceutical companies on precise tumor diagnosis is actually not uncommon
.
On November 23, Jiuqiang Biotech and Zhongkonate held a cooperation signing ceremony
.
This in-depth cooperation between the two parties includes two levels: one is the equity investment of Nine Biotech Co.
, Ltd.
; the other is the signing of a sales cooperation agreement between Nine Biotech and China Conatech, becoming the head of the domestic medical institution for the entire line of CTC products of China Conatech.
Dealer
.
It is expected that through this cooperation, Zhongkenatei's technical advantages in the field of CTC liquid biopsy will be organically combined with the powerful channel capabilities of the nine-strong biological in the field of inspection, and jointly create a professional enterprise for multi-faceted accurate tumor diagnosis
.
On November 7, Roche Diagnostics (Shanghai) Co.
, Ltd.
also announced a strategic partnership with Preh Benchmark at the 4th China International Import Expo.
.
This cooperation will combine the technical advantages of both parties in the field of precision medicine to jointly promote the development and cooperation of precision tumor diagnosis, and promote the realization of clinical precision diagnosis and treatment
.
Analysis believes that a large number of companies are vying to deploy in the field of accurate tumor diagnosis.
In fact, they are mainly optimistic about the development prospects of China's diagnostic industry
.
It is understood that in recent years, the financing environment of China's diagnostic and genetic testing industry has begun to tighten further, with significant head effects in the field of private equity financing, and genetic testing companies are at the forefront in both the number of transactions and the amount of financing
.
In addition, since the launch of the Sci-tech Innovation Board, IVD has also become a popular segment in the biomedical sector; the M&A market has completed two major transactions exceeding RMB 1 billion throughout the year
.
At the same time, more than half of financing transactions in overseas markets are also completed by genetic testing companies
.
In this context, industry insiders believe that in the medium and long term, as people’s consumption levels upgrade, the number of patients with chronic diseases and the increase in health awareness due to the increasing aging of our country will be used in disease risk prediction and health management.
With higher requirements and demands in chronic disease management and other aspects, the diagnostic testing industry will continue to be valued, and the market will further expand
.
Affected by this, China's medical diagnosis-related enterprises are also expected to usher in continued benefits
.
